Commercializing a therapy utilizing large numbers of active T cells to attack solid tumors, providing a meaningful clinical response in disease areas and patient populations where other approaches are not effective. The Company has a proprietary cell therapy platform (autologous tumor infiltrating lymphocytes (TILs)) and is conducting Phase 2 trials with for treatment of patients with advanced solid tumors including melanoma, cervical cancer, head and neck cancer and non-small cell lung cancer; development plan is to secure accelerated initial registration in areas of particularly significant need and low response from current treatment options. Demonstrated objective response rate (ORR) of 38% and disease control rate of 77% in 47 late stage refractory patients with advanced melanoma; executing a fast track development plan via a single arm registration study.
999 Skyway Road
San Carlos, CA 94070
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by